Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It makes no sense to compare AD bios by their respective share price.
MC is the true value for comparisons:
SAVA ***** 741 Million USD
ANVS ***** 92 M
CRTX ***** 70 M
AVXL ***** 880 M
AVXL leading the pack recently and pulling away.
I think the winner of being the SOC for Rett Syndrome is without a doubt will be Anavex.
The new clue is what the 'Reverse Rett' organization bluntly had to say regarding Acadia's drug Trofinetide:
H.C. Wainwright Keeps Their Buy Rating of $42 on Anavex Life Sciences,
https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/stock-news/88733479/h-c-wainwright-keeps-their-buy-rating-on-anavex-l
Powerwalker, thanks for the explanation. I'm wondering why Yahoo Financials directed me to the Aussie stock market when I typed in the company name.
"Red, you had the Aussie stock market, which closed before today's PR."
Investor, I typed in on Yahoo Financials " Neuren " per your post because I did not know the symbol for "Neuren" and got this:
Neuren Pharmaceuticals Limited (NEU.AX)
ASX - ASX Delayed Price. Currency in AUD
5.27 -0.33 (-5.89%)
-----------------------------------------
I did not know about NURPF, thanks for that info.
Investor, I don't think this is correct:
" Neuren is up 50% "
Day's Range 5.25 - 5.44
" (20%) left the trial" ,,, I think that says the ones who just dropped out was because of the side effects were just too much, but I'm pretty sure many more experienced the side effects but are hanging in there on hope that there would be some improvement, even if small.
These parents are desperate for anything that might help.
This bodes extremely well for Anavex becoming the SOC once A2-73 Blarcamesine is in use side by side with Acadia's drug and parents make a choice.
The short sale volume percent (not short interest) for stock ticker AVXL is 62% on Aug 02, 2022.
The short sale volume is 219,722. The total volume is 356,607.
The short sale volume percent is up 5% compare to Aug 01, 2022
(See on the chart just how much shares are sold short daily, it is a very significant amount of the daily volume.)
http://shortvolumes.com/?t=AVXL
The short sale volume percent (not short interest) for stock ticker AVXL is 62% on Aug 02, 2022. The short sale volume is 219,722. The total volume is 356,607. The short sale volume percent is up 5% compare to Aug 01, 2022.
http://shortvolumes.com/?t=AVXL
Thanks Mayo once again for your outstanding analysis of the data and for sharing it here and other stock board venues.
AVXL Due Diligence for new eyes and reference material for old eyes - 8 Sources:
Update Compendium, a 3rd party independent review and projections with data and sources.
Projected Blarcamesine Revenues & Market Cap; plus a wealth of other data and important details. Compiled by Mayo:
https://www.sotcanalytics.com/update-compendium
Jun 2022 Commentary on Anavex's First Educational Video.
A report from various members of the company management team on current operations and future projections:
https://www.anavex.com/vnrjune2022
NEWS: Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
https://www.anavex.com/post/anavex-announces-first-entire-clinical-alzheimer-s-gene-pathway-data-of-anavex-2-73-at-aaic-2022
June Corporate Slides.
Very useful for a visual look at all the Anavex programs, trials, graphs, and useful data:
https://www.anavex.com/_files/ugd/850d88_6d847f744209465f82a4ad655bb25941.pdf
Piotrpeterblog.com is an independent analysis blog on Alzheimer and CNS Drugs.
https://piotrpeterblog.com/
An extensive list of a wide range of various topics with links, compiled DD, and recent posts. Compiled by XenaLives
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166917727
A report given by Dr. Randi Hagerman, a recognized leader WW for CNS conditions and treatments. Compiled by tradeherpete.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168422630
Anavex Company, an Overview; compiled by Mayo Mobile:
https://drive.google.com/file/d/15i9suShnAjC_Vq5gEl-ocp3ebsWKr0fd/view
Good luck with the DD, feel free to ask the knowledgeable board any questions.
RedShoulder
sab I agree with what you are saying about the 50 day moving average of these AD stocks, and I have watched it happen too as I check these stocks daily. My post was just about what is happening to AD Bios today based on the SAVA news today.
I think it is odd that AVXL has been in the red all day while ANVS and ACAD did not get the sell treatment. I'm not concerned as this will be just a short period of adjustment.
Who in their right mind is buying the SAVA $17 shares being sold today after the news of an investigation by the Justice Dept being launched on SAVA ?
Thanks Xena for posting the new short data. It shows a very slow short covering from the historic high, it is going to take some good news and high buy volume to accelerate the short covering, and maybe create a short squeeze.
07/15/2022 *** 8,260,601
06/30/2022 *** 8,707,363
06/15/2022 *** 9,497,126
05/31/2022 *** 8,908,532
05/13/2022 *** 8,775,909
04/29/2022 *** 8,133,566
04/14/2022 *** 7,880,667
03/31/2022 *** 7,614,059
SP just spiked straight up. Went from 10.83 to 11.15 in minutes. From red to green.
Anybody know why, as that kind of move is unusual?
AVXL Due Diligence for new eyes and reference material for old eyes - 7 Sources:
Update Compendium, a 3rd party independent review and projections with data and sources.
Projected Blarcamesine Revenues & Market Cap; plus a wealth of other data and important details. Compiled by Mayo:
https://www.sotcanalytics.com/update-compendium
Jun 2022 Commentary on Anavex's First Educational Video.
A report from various members of the company management team on current operations and future projections:
https://www.anavex.com/vnrjune2022
June Corporate Slides.
Very useful for a visual look at all the Anavex programs, trials, graphs, and useful data:
https://www.anavex.com/_files/ugd/850d88_6d847f744209465f82a4ad655bb25941.pdf
Piotrpeterblog.com is an independent analysis blog on Alzheimer and CNS Drugs.
https://piotrpeterblog.com/
An extensive list of a wide range of various topics with links, compiled DD, and recent posts. Compiled by XenaLives
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166917727
A report given by Dr. Randi Hagerman, a recognized leader WW for CNS conditions and treatments. Compiled by tradeherpete.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168422630
Anavex Company, an Overview; compiled by Mayo Mobile:
https://drive.google.com/file/d/15i9suShnAjC_Vq5gEl-ocp3ebsWKr0fd/view
Good luck with the DD, feel free to ask the knowledgeable board any questions.
RedShoulder
powerwalker, I was just furnishing a source link covering various AVXL short sale data that is available which may or may not be of interest to the individual member of this AVXL MB.
I thought the note that 'Short sale restricted for 2022-07-19' and the 'Fails-To-Deliver Data from the SEC' graph was interesting interesting to me.
I did not see it as "innuendos" (?), pretty much just direct data as stated.
GLTY.
AVXL: Information regarding various Short Sale data and tables:
Note: "Short Sale restricted for 2022-07-19",
"Fails-To-Deliver Data" and graph,
"Short Interest settlement table, with current total short interest reported.'
"Short Borrow Availability and Fee Rate"
"Short Borrow Availability and Fee Rate"
"Show borrow data chart for:"
Etc.
https://www.shortablestocks.com/user/index.cgi?AVXL
Another Million Vol day.
Gator, I believe that PDD has the best odds for FDA approval since the Ph-2 trial data shows that over 90% on high dose improved (92%?). I give PDD on high dose a 90% chance for FDA approval because no other drug has ever improved PDD. The need is great and the drug is very safe. I think A2-73 is an outright win for PDD.
You Alzheimer low odds do not match the fact that in the PH-2 trial some reversed the disease and I know of 3 videos showing that, then some others did not decline and remained stable. I know it was a small trial, however that does not negate the fact no drug in history has had results showing some improved to a normal state and some became stable and did not decline.
Besides efficacy being excellent the drug is safe with no adverse events, and that carries a lot of weight with the FDA is considering approval.
Vol just went over a million shares with lots of time left before the close.
$AVXL Due Diligence - 5 Sources:
Update Compendium, a 3rd party independent review and projections with data and sources.
Projected Blarcamesine Revenues & Market Cap; plus a wealth of other data and important details. Composed by Mayo:
https://www.sotcanalytics.com/update-compendium
Jun 2022 Commentary on Anavex's First Educational Video.
A report from various members of the company management team on current operations and future projections:
https://www.anavex.com/vnrjune2022
June Corporate Slides.
Very useful for a visual look at all the Anavex programs, trials, graphs, and useful data:
https://www.anavex.com/_files/ugd/850d88_6d847f744209465f82a4ad655bb25941.pdf
An extensive list of a wide range of various topics with links, compiled DD, and recent posts. Compiled by XenaLives.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166917727
A report given by Dr. Randi Hagerman, a recognized leader WW for CNS conditions and treatments. Composed by tradeherpete.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168422630
Good luck with the DD, feel free to ask the knowledgeable board any questions.
RedShoulder
AVXL Market Cap moves back into +Billion territory currently at 1.008 B.
SAVA Market Cap is currently down to 959,813 M.
AVXL Due Diligence Sources for new eyes and reference material for old eyes.
Update Compendium, a 3rd party independent review and projections with data and sources.
Projected Blarcamesine A2-73 , A3-71 Revenues & Market Cap; plus a wealth of other data and important details. Composed by Mayo:
https://www.sotcanalytics.com/update-compendium
Jun 2022 Commentary on Anavex's First Educational Video.
A report from various members of the company management team on current operations and future projections:
https://www.anavex.com/vnrjune2022
June Corporate Slides.
Very useful for a visual look at all the Anavex programs, trials, graphs, and useful data:
https://www.anavex.com/_files/ugd/850d88_6d847f744209465f82a4ad655bb25941.pdf
An extensive list of a wide range of various topics with links, compiled DD, and recent posts. Compiled by XenaLives.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166917727
A report given by Dr. Randi Hagerman, a recognized leader WW for CNS conditions and treatments. Composed by tradeherpete.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168422630
Good luck with the DD, feel free to ask the knowledgeable board any questions.
RedShoulder
Last short report shows 8,707,363 shorted. That $111,976,688 to protect from the short side view.
The Trade in USD: $1,744,400
nidan, 49% of the trades were shorts; to me it says they want to keep a lid on the SP.
We need a good news PR with lots of buy volume to break free, and force the shorts into buying to cover.
"The short sale volume percent (not short interest) for stock ticker AVXL is 49% on Jul 13, 2022. The short sale volume is 164,607. The total volume is 334,228."
http://shortvolumes.com/?t=AVXL
15 of the last 19 trading days have been green candles. A pretty strong trend, especially in this market.
https://www.barchart.com/stocks/quotes/AVXL/interactive-chart
One nice size AH trade 16:32:10__$12.78__25,041 sh
https://www.nasdaq.com/market-activity/stocks/avxl/after-hours
"$13+ afterhours. I think the runup to alz data readout has officially begun."
Consolidated Last Sale $13.08 +0.30 (+2.35%)
After-Hours Volume 50,951
After-Hours High $13.12 (04:16:07 PM)
After-Hours Low $12.78 (04:42:30 PM)
Lots of time left before the close at this time 6:30 et
https://www.nasdaq.com/market-activity/stocks/avxl/after-hours